Anteris Technologies Postpones Special Stockholder Meeting

“`html

09/19/2025 – 02:30 AM

MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company focused on pioneering next-generation medical devices, announced the adjournment of its Special Meeting of Stockholders on Thursday, September 18, 2025, due to a lack of quorum. The meeting has been rescheduled for Monday, September 29, 2025, at 8:00 a.m. Central time (being 11:00 p.m. AEST on Monday, September 29, 2025). The rescheduled meeting will also be held virtually via live webcast at www.virtualshareholdermeeting.com/AVR2025SM.

The record date for stockholder eligibility remains August 11, 2025. The adjournment aims to provide stockholders additional time to cast their votes on proposals outlined in the definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on August 18, 2025.

Anteris’ Board of Directors has unanimously recommended that stockholders vote in favor of all proposals presented in the Proxy Statement.

Voting Details and Stockholder Action

Stockholders who have already submitted their votes or directed CHESS Depositary Nominees Pty Ltd (“CDN”) to vote their CHESS Depositary Interests (“CDIs”) need not take further action unless they wish to change their vote.

For those holding shares of common stock as of the Record Date (August 11, 2025) who have yet to vote, the company encourages them to do so promptly, following the instructions outlined in the Proxy Statement. To ensure timely receipt and processing, proxies submitted online or via telephone must be received by 11:59 p.m. Eastern Time on September 28, 2025 (being 1:59 p.m. AEST on September 29, 2025). Mail-in proxies must be received prior to the close of business on September 26, 2025 (being 7:00 a.m. AEST on September 27, 2025).

CDI holders who have not yet directed CDN to vote must submit their completed CDI Voting Instruction Form to Computershare, Anteris’ designated agent for CDI voting, by 5:00 p.m. Central Time on September 25, 2025 (being 8:00 a.m. AEST on September 26, 2025), in accordance with instructions provided on the voting instruction form.

Strategic Implications and Delay Analysis

The adjournment of the Special Meeting underscores the challenges faced by companies, particularly those with global operations and dual listings, in securing sufficient quorum for important shareholder votes. Analysts suggest that factors such as retail investor engagement, institutional shareholder voting policies, and the complexity of cross-border voting mechanisms can contribute to such delays.

The proposals under consideration at the Special Meeting are likely to have significant implications for Anteris’ future strategic direction. Failure to achieve a quorum and secure approval could potentially delay key corporate initiatives, impacting the company’s ability to execute its growth strategy and capitalize on market opportunities.

Anteris Technologies: Focused on DurAVR™ and ADAPT® Tissue Technology

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) stands at the forefront of structural heart innovation, driven by a commitment to restore healthy heart function through cutting-edge medical devices.
Leveraging its core technological assets, particularly the DurAVR^® THV and ADAPT^® tissue technology, Anteris is positioning itself to address critical needs in the global market for aortic stenosis treatments.

Important Additional Information

The definitive Proxy Statement, filed with the SEC on August 18, 2025, contains comprehensive information regarding the proposals under consideration and is the primary reference document for stockholders. This notice provides updated information that, in the event of any inconsistencies, supersedes the information provided in the Proxy Statement.

The company urges all stockholders to carefully review the Proxy Statement (and any subsequent amendments or supplements) and other relevant SEC filings to make informed voting decisions. These documents are available for free on the SEC’s website (https://www.sec.gov) and the “SEC Filings” section of Anteris Technologies’ investor relations website (https://www.anteristech.com/investors).

About Anteris Technologies

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. The company’s multi-disciplinary team is focused on delivering innovative solutions for structural heart disease patients.

Anteris’ lead product, the DurAVR^® Transcatheter Heart Valve (THV), is designed to treat aortic stenosis. This balloon-expandable THV is designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The DurAVR^® THV is composed of a single piece of molded ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. The DurAVR^® THV System includes the DurAVR^® valve, the ADAPT^® tissue, and the balloon-expandable ComASUR^® Delivery System.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are identified by the use of terms such as “believe,” “project,” “expect,” “anticipate,” “estimate,” and are based on current expectations and assumptions. Forward-looking statements include statements regarding the presence of a quorum at the Special Meeting and the receipt of approvals for the proposals.
These forward-looking statements are subject to risks, uncertainties, and assumptions. Readers are cautioned against placing undue reliance on forward-looking statements. The company does not assume any obligation to update these statements to reflect actual results or revised expectations, except as required by law.